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Abstract: Nanoparticles have become a powerful tool in oncology not only as carrier of the highly
toxic chemotherapeutic drugs but also as imaging contrast agents that provide valuable information
about the state of the disease and its progression. The enhanced permeation and retention effect for
loaded nanocarriers in tumors allow substantial improvement of selectivity and safety of anticancer
nanomedicines. Additionally, the possibility to design stimuli-responsive nanocarriers able to
release their payload in response to specific stimuli provide an excellent control on the administered
dosage. The aim of this review is not to present a comprehensive revision of the different theranostic
mesoporous silica nanoparticles (MSN) which have been published in the recent years but just to
describe a few selected examples to offer a panoramic view to the reader about the suitability and
effectiveness of these nanocarriers in the oncology field.
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1. Introduction
Nanoparticles have become a powerful tool in the clinical field, not only by their capacity to
deliver drugs to diseased tissues in a controlled and selective manner [1], but also by their ability
to simultaneously provide information about the stage of the disease progression [2]. Nanosystems
endowed with these dual functions, drug delivery, and diagnosis, received the name of theranostic
nanocarriers. Among the different clinical applications of these smart nanocarriers, antitumoral
therapy have received the highest attention [3]. The origin of this interest began in 1986, when Maeda
and Matsumura reported the passive tendency of intravenously injected nanometric agents to be
accumulated within solid tumors [4]. The accelerated growth of solid tumors demands the rapid
construction of tumoral blood vessels in order to provide the required nutrients to sustain them.
These vessels are built in an uncontrollable manner presenting wide interendothelial junctions which
create pores with diameters with up to a few hundreds of nanometers [5]. Thus, when nanoparticles
that were injected in the blood stream reach the tumoral tissue, they can pass through these fenestrations
being selectively accumulated there. Moreover, solid tumors usually present inefficient drainage system.
This is a consequence of the compression of lymphatic vessels due the expansion of tumoral tissue,
which enhances the retention time of the nanoparticles within the diseased tissue. The combination
of these two characteristics, high permeability of tumoral blood vessels and inefficient drainage,
constitutes to the gold standard of the use of nanoparticles in oncology and receives the name of
enhanced permeation and retention (EPR) effect [6]. The discovery of EPR effect triggered the race to
design nanocarriers capable to selectively deliver chemotherapeutic agents to tumoral tissue reducing
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the systemic toxicity caused by these drugs in healthy tissues. Thus, a vast number of different
nanoparticles composed of both organic materials as polymers [7], lipids [8], and dendrimers [9]
as well as by inorganic ones such as metals [10], ceramics [11], and carbon allotropes [12], among
others have been reported exhibiting excellent drug delivery capacities. The selectivity of these
nanocarriers has been enhanced anchoring targeting moieties such as antibodies [13], aptamers [14],
proteins [15], peptides [16], and small molecules [17] on their surface. Additionally, the incorporation
within the nanocarrier of imaging agents as molecular fluorophores [18], magnetic nanocrystals [19],
ultrasound contrast agents [20], or radionuclides [21] allow the combination of therapy and diagnosis
in one single theranostic nanocarrier. In the recent years, EPR effect has been object of an intense
debate by the scientific community because many human tumors lack these highly permeable blood
vessels and therefore, the efficacy of nanomedicines could be compromised [22]. Wilhem et al. have
reported that only around 0.7% of the injected nanoparticles are accumulated in tumoral tissues that
it would be not enough to induce significant therapeutic effects [23]. However, some recent studies
suggested that nanoparticles enter into solid tumors by active mechanisms of transcytosis instead
of by passive diffusion through the tumoral blood vessel gaps [24,25]. Moreover, increasing the
dose of nanoparticles through co-administration of drug-loaded and empty nanocarriers improves
nanoparticle accumulation in tumors up to 12% by saturation of Kupffer cells which are one of the
main players of nanoparticle clearance [26]. Additionally, several other barriers as interstitial pressure
within the tumor, hemodynamic considerations, or off target cellular uptake should be addressed to
improve the selectivity and efficacy of nanomedicines [27,28]. Among the high variety of nanomaterials
capable of transporting drugs, each of them with their advantages and liabilities, mesoporous silica
nanoparticles (MSN) stands out by their unique properties as high loading capacity because of their
external surface in the range of 1000 m2 per gram, high chemical, mechanical and thermal robustness,
easy functionalization with different moieties and excellent biocompatibility [29]. MSN present a
honeycomb-like pore network in which the pore channels are parallel without any interconnections
between them. This unique pore network allows an outstanding control of the drug release behavior
because of the capacity to block the pore outlets with different gatekeepers sensible to external or
internal stimuli [30,31]. Thus, different gatekeepers can be anchored on the pore outlets through
stimuli-responsive cross-linkers or responsive polymer shells in order to control the drug release process
avoiding or allowing the drug departure in response to specific internal (pH, redox, enzymes, etc.,) or
external stimulus (temperature, magnetic fields, ultrasounds, light) [32]. Additionally, MSN surface
can be easily decorated with different functionalities as amino, thiol, or carboxylic groups, among
others, which enhance the affinity of the housed drugs by the pore walls improving the drug-loading
capacity [33]. There are different synthetic methods to produce MSN with multiple sizes, shapes,
pore diameter, and pore network structures [34]. This variety allows to produce MSN designed to
house diverse therapeutic agents, from small cytotoxic drugs to large proteins or oligonucleotide
strands. These smart MSN are an elegant platform to deliver therapeutic agents to tumoral tissues
enhancing not only the selectivity in the delivery but also controlling the administered dosage with
high accuracy. The aim of this review is not to present a comprehensive revision of the different
theranostic MSN which have been published in the recent years [35,36] but just to describe a few
selected examples to offer a panoramic view to the reader about the suitability and effectiveness of
these nanocarriers in the oncology field. For the sake of clarity, these nanosystems are categorized in
different sections according to the associated imaging technique.
2. Optical Theranostics
Light has been widely employed in nanomedicine both to trigger drug release and to interrogate
the diseased tissue in order to harvest clinical information [37]. This stimulus present advantages
such as excellent biocompatibility and easiness to focalize its action in specific zones. However, it also
exhibits a strong limitation which is its poor penetration in biological tissues. Light in the visible (VIS)
and ultraviolet region (UV) are rapidly adsorbed by hemoglobin and therefore, it barely penetrates
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in the tissue. Near infrared radiation (NIR) is scarcely adsorbed and can penetrate up to 10 cm into
biological tissues. This light source is being widely used to treat tumoral tissues by photodynamic
therapy (PDT). PDT is based on the use of specific molecules, called photosensitizers, capable to
generate singlet oxygen species under exposition of NIR. One of the main problem of PDT is the
non-selective biodistribution of the administered photosensitizers which can cause side reactions as
skin photosensitivity. In order to avoid this problem, photosensitizers have been loaded in targeted
nanoparticles which can be selectively located in the diseased tissue. Hollow MSN have been loaded
with indocyanine green (ICG) which is a FDA approved photosensitizer that exhibit a short blood
half-life of 2–4 min if it is intravenously administered in free form [38]. When ICG is loaded within
the nanoparticle, its capacity to generate singlet oxygen species is reduced because of self-quenching
caused by aggregation. Therefore, this photosensitizer is transported in an inactivated (OFF) state.
Once the nanocarriers are engulfed by tumoral cells, ICG is released inside the cell being activated
(ON) to generate oxidative species under NIR capable to destroy the tumoral cells. Zhang et al. have
decorated the external surface of MSN with metalloproteinase-sensitive fluorophores which are only
activated in the tumoral tissue [39]. Certain proteolytic enzymes as metalloproteinases MMP-2 are
overproduced by tumoral tissues to digest the extracellular matrix (ECM) allowing the colonization
of the surrounding tissues by malignant cells. TAMRA fluorophore was conjugated to a specific
peptide Pro-Leu-Gly-Val-Arg (PLGVR) which is cleavable by MMP-2. On the other end of this peptide,
a fluorescence quencher (Dabcyl) was also anchored to suppress the TAMRA fluorescence. These
nanocarriers were loaded with a potent cytotoxic drug, camptothecin (CPT), which was retained inside
the pore network by the presence of these moieties on pore outlets that act as pore blockers. When the
nanoparticle reaches the tumoral tissue, the presence of MMP-2 cleaves this peptide triggering the
drug departure and activating the TAMRA fluorescence that becomes visible to the nanoparticle by
fluorescence imaging. The selectivity against tumoral cells was provided by anchoring cyclo-RGD
which binds to αβ-integrins receptors usually overexpressed by many tumoral cell lines. Jeon et al.
have encapsulated 1,1′-dioctadecyl-3,3,30,30-tetrametylindotrucarbocyanine iodide (DIR) within the
pore network of MSN decorated with polyethyleneglycol (PEG) [40]. The presence of this dye allows
the visualization of these nanoparticles by in vivo fluorescence imaging which have been used to
monitor tumoral tissues and ischemic lesions. Additionally, laser irradiation at 808 nm of breast tumors
in mice model treated with these DIR-loaded nanocarriers showed a significant tumor reduction by
photothermal therapy (PTT) due to temperature increase in the zone. Fluorescent MSN decorated
with the aptamer YQ26 have been employed to visualize tumoral blood vessels in mice models [41].
Aptamers are single-stranded DNA or RNA sequences that adopt 3D conformations able to selectively
bind to certain molecules as proteins, peptides, sugars, ions, or phospholipids. The specific binding
capacity of these oligonucleotide strands have been used to enhance the selectivity of the nanomedicines.
YQ26 shows excellent capacity to bind to the homodimeric transmembrane glycoprotein, endoglin
(END), which is highly expressed by tumoral blood vessels but not by healthy ones. The injection of
these fluorescent nanoparticles allowed the in vivo visualization of the tumoral vasculature (Figure 1).
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Figure 1. In vivo imaging of tumor-bearing mice after the injection of mesoporous silica nanoparticles 
(MSN) decorated with YQ26 aptamer. Left image shows the accumulation of nanocarriers in the 
tumor located in the flank of the mice. The graph located in the right quantified the accumulation of 
nanocarrier by fluorescence. *** P < 0.001. Reproduced from [41], Ivyspring International Publisher, 
2017. 
Yao et al. have developed MSN capped with cell-penetrating polydisulfides. These pore-
blockers enhance cell endocytosis at the same time that maintain the drug housed within the 
nanocarrier until they are degraded by reductive species as glutathione present in the intracellular 
space [42]. These nanocarriers were capable of releasing small molecule inhibitors and anti-miR-21. 
The release of these agents caused tumoral cell apoptosis. Additionally, the incorporation of caspase-
sensitive fluorogenic probe into the MSN surface provided information of its own apoptotic process. 
Apoptosis is a cell death program mediated by the expression of certain proteolytic enzymes known 
as caspases. Thus, the apparition of fluorescence inside tumoral cells treated with these nanocarriers 
confirm the apoptosis activation induced by the release of the transported drugs. The incorporation 
of molecular probes sensible to light is one way of providing optical properties to the nanocarriers, 
but the other strategy is to incorporate other nanoparticles within a nanocarrier. Carbon dots (CDs) 
are excellent optical probes because of their high photostability, low toxicity, and water dispersibility. 
Hollow MSN that contains CDs and doxorubicin were intratumorally injected into breast tumor mice 
models inducing a potent tumoral growth inhibition which was observed by in vivo fluorescent 
imaging [43]. Dox release was accelerated by the more acidic conditions present in the tumoral tissue 
and also in the endosomes of the tumoral cells. CD have been anchored on the pore outlets through 
redox-sensitive linkers in order to block drug departure and to act as fluorescent imaging agents at 
the same time [44]. This design allows a better control on drug release because it only takes place 
when the nanocarrier are exposed to the reductive environment present in the cytosol. The size and 
shape of CD determine the optical window in which they can be observed which enhances their 
potential applications [45]. CuS nanoparticles have been incorporated on the surface of MSN to 
exploit their capacity to generate mild hyperthermia in the tumoral tissue by exposition to NIR [46]. 
MSN surface was decorated with thiol groups to provide anchoring points to CuS nanoparticles. Dox 
was loaded within the pore network, with their release being mediated by the presence of three 
stimuli, glutathione within the tumoral cells, mild acidic conditions in the tumor, and laser 
irradiation. Dox release was monitored by the red fluorescence signal of this molecule. 
3. Photoacustic Theranostics 
An imaging technique that combines light and ultrasound is photoacoustic imaging (PA). PA 
employs light contrast agents that produce heat under NIR irradiation. This heat induces 
Figure 1. In vivo imaging of tumor-bearing mice after the injection of mesoporous silica nanoparticles
(MSN) decorated with YQ26 aptamer. Left image shows the accumulation of nanocarriers in the tumor
located in the flank of the mice. The graph located in the right quantified the accumulation of nanocarrier
by fluorescence. ∗∗∗ p < 0.001. Reproduced from [41], Ivyspring International Publisher, 2017.
Yao et al. have developed MSN capped with cell-penetrating polydisulfides. These pore-blockers
enh nc cell endocytosis at the same time that maintain the drug housed within the nanocarrier
until they re degrade b reductive species as glutathio e present in the intracellular space [42].
These nanocarriers w re capable of releasing small molecule inhibito s a d an i-miR-21. The release
of these ag nts caused tumoral cell poptosis. Additionally, the incorporatio of caspase-sensitive
fluorogenic probe into the MSN surface provided information of its ow apoptotic process. Apoptosis
is a cell death program mediated by the expression of certain proteolytic enzymes known as caspases.
Thus, the apparition of fluorescence inside tumoral cells treated with these nanocarriers confirm the
apoptosis activation induced by the release of the transported drugs. The incorporation of molecular
probes sensible to light is one way of providing optical properties to the nanocarriers, but the other
strategy is to incorporate other nanoparticles within a nanocarrier. Carbon dots (CDs) are excellent
optical probes because of their high photostability, low toxicity, and water dispersibility. Hollow
MSN that contains CDs and doxorubicin were intratumorally injected into breast tumor mice models
inducing a potent tumoral growth inhibition which was observed by in vivo fluorescent imaging [43].
Dox release was accelerated by the more acidic conditions present in the tumoral tissue and also in the
endosomes of the tumoral cells. CD have been anchored on the pore outlets through redox-sensitive
linkers in order to block drug departure and to act as fluorescent imaging agents at the same time [44].
This design allows a better control on drug release because it only takes place when the nanocarrier are
exposed to the reductive environment present in the cytosol. The size and shape of CD determine
the optical window in which they can be observed which enhances their potential applications [45].
CuS nano articles have been i cor o ated on the surface f MSN to exploit their capacity to generate
mild hyperthermia in the tumoral tissue by exposition o NIR [46]. MSN surface was decorated with
thiol groups to pr vide anc oring points to CuS n oparticles. Dox was loaded within the pore
network, i their release being media ed by the presence of thr e stimuli, glutathi ne within the
tumoral cells, mild acidic conditions in the tumor, and laser irradiation. Dox release was monitored by
the red fluorescence signal of this molecule.
3. Photoacustic Theranostics
An imaging technique that combines light and ultrasound is photoacoustic imaging (PA).
PA employs light contrast agents that produce heat under NIR irradiation. This heat induces
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thermoelastic changes in the tissue which generate ultrasound waves that can be detected by US
transducers. One widely photoacoustic contrast agent is ICG. This dye has been covalently grafted on
MSN which contain on the surface a chemotherapeutic drug, mitoxantrone (MTX), which also exhibits
NIR adsorption properties [47]. The conjugation of ICG on MSN increases the photoluminescence
efficiency as well as its chemical stability. Injection of these nanocarriers in syngeneic breast tumor
murine model showed that both PA signals corresponding to ICG and MTX were detected at 810 nm and
700 nm, respectively. Furthermore, the evaluation of the ratio PA700 nm/PA810 nm confirmed the MTX
release due to the significant reduction of MTX signal during the time. ICG has been encapsulated in
core-shell MSN which contains a upconversion nanoparticle core formed by two different composition
of NaYF4/Yb/Er [48]. Irradiation of these nanocarriers at 800 nm induced light harvesting of NIR
and upconversion to green and red luminescence by the core which can be employed for optical
imaging and heat production by ICG that can be detected by PA. Nanocarriers injected in brain vessels
of mice were visualized by PA during longer times than free ICG as a consequence of the longer
stability and residence time in the tissue. Finally, the PTT efficacy of these nanoparticles was tested
in tumor-bearing mice models by intratumoral injection followed by NIR irradiation after one week.
Mice treated with the nanocarriers and exposed to NIR exhibited smaller tumor sizes and growth
in comparison with non-treated animals. ICG has been encapsulated in liposomes which wrapped
Gd-doped MSN loaded with Dox to combine therapy, by light-responsive Dox release induced by
the heat generated under NIR that distort the liposomal coating, and imaging with PA, fluorescence
imaging and MRI [49]. Perfluoropentane (PFP) have been loaded within core-shell nanoparticles
formed by a core of gold nanorods and a mesoporous silica shell [50]. When the system was irradiated
with NIR at 808 nm, the gold nanorods generated enough heat to induce liquid–gas phase transition of
PFP. This process produced PFP bubbles which were transformed into microbubbles by coalescence.
The generation of these microbubbles enhanced the accumulation of the nanocarriers within the
malignant tissue [50]. These nanoparticles were detected by PA and ultrasound (US) imaging because
of the echogenic properties of the generated microbubbles. The efficacy of the system was evaluated in
melanoma-bearing mice model in which the point of maximal nanoparticle accumulation in the tumor
(24 h) was determined by PA and US imaging. At this time, the tumors were irradiated with NIR laser
at 808 nm (1 W·cm−2 during 5 min) reaching a temperature in the tissue of 46.2 ◦C. Tumors treated
with these nanocarriers and NIR exposition were completely eliminated on day 18 after the injection.
4. Ultrasound Theranostics
US imaging is one of the most employed technique in the clinical practice because of its high
penetration capacity, low cost, non-invasive, and non-ionizing nature. Different gas-filled organic
nanocarriers have been employed to generate micro-bubbles acting as echogenic nanomaterials [51].
The micro-bubbles encapsulated in elastic shells vibrate and oscillate under US application acting as
contrast agents. However, these nanocarriers usually present large sizes in the micrometer scale and low
stability that compromise their clinical applications. Inorganic US contrast agents have higher stability
and can be fabricated with smaller sizes than their organic counterparts [52]. In this case, the contrast
agent properties of these rigid systems are based on the inhomogeneity that they introduce in the tissue
instead of vibrations. Different inorganic nanomaterials have been employed as US contrast agents
such as Au, TiO2, carbon nanotubes, and MSN [53]. MSN functionalized with the monoclonal antibody
Herceptin® have been employed to treat and diagnose breast cancer [54]. Herceptin® binds to the
human epidermal growth factor receptor 2 (HER2), which is usually upregulated in some types of breast
tumors. In vitro culture of HER2 + breast cancer cells treated with anti-Her2-MSN produced a spike in
the US contrast around 640% with a boundary thickness of 1 mm proving their capacity to improve US
imaging in these tumors. Rattle-type MSN have exhibited higher US contrast than MSN or hollow
MSN because of the existence of two interfaces that generate double scattering/reflection in comparison
with the other types of nanoparticles that present only one interface [55]. The incorporation of
enzyme-degradable shells on MSN as polycaprolactone has been reported to accelerate the nanoparticle
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degradation in biological fluids which contains lipases. This strategy improves the nanocarrier
biocompatibility at the same time that increases its elasticity and US contrast agent behavior [56].
US have also been used to trigger the drug departure from MSN. Paris et al. have coated the
MSN surface with a US-sensitive polymeric shell in order to retain cytotoxic drugs within the silica
matrix until US exposition [57]. The stimuli-responsive release is provided by the incorporation of
the thermosensitive polymer poly (2-(2-methoxyethoxy) ethyl methacrylate) (p (MEO2MA)) which
contains 2-tetrahydropyranyl methacrylate (THPMA). This type of thermosensitive polymers exhibits
linear-to-globular transitions in response to temperature rise and this transition temperature can be
tuned by the introduction of hydrophilic monomers into the polymer composition. Under 10 min of
US irradiation, the acetal group of THPMA was cleaved forming hydrophilic methacrylic acid (MAA)
which increased the transition temperature of the polymer opening the pores that triggered the drug
release (Figure 2).
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in the tumoral tissue. Nanoparticles can reach the tumoral zone by EPR effect but once there, their 
penetration into the tissue is hardly compromised as a consequence of the presence of positive 
intratumoral pressure which pushes the nanocarriers away from the tumor [58] and by the slow 
diffusion rate of nanometric objects [59]. These limitations can be partially overcome by the 
incorporation proteolytic enzymes into the nanocarrier surface to digest the extracellular matrix and 
enhance the diffusion of the nanocarrier within the cancerous tissue [60]. One interesting approach 
to improve nanoparticle penetration is the use of focalized US to propel them into the tissue. The co-
injection of dye-loaded MSN with sub-micrometric cavitation nuclei that enhances the US effect 
produced a significantly increased penetration of MSN in in vitro tumoral blood vessel models by 
the application of US [61]. MSN were extravasated from the blood vessel propelled by the violent 
collapse of gas bubbles generated by inertial cavitation. The co-administration of cavitation nuclei 
reduced the pressure required to induce inertial cavitation by half which allows to propel the 
nanocarriers employing conventional clinical US apparatus. 
5. Magnetic Resonance Theranostics 
The application of magnetic fields to interrogate the disease progression by magnetic resonance 
imaging (MRI) has important advantages such as excellent tissue penetration, high spatial resolution, 
and harmless radiation. There are two main types of contrast agents for MRI: gadolinium (Gd) or 
manganese chelates [62], as T1-weighted positive agents and superparamagnetic iron oxide 
nanoparticles (SPION) [63], as T2-weighted negative agents, respectively. MRI is based on the 
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5. agnetic Resonance Theranostics
The application of magnetic fields to interrogate the disease progression by magnetic resonance
imaging (MRI) has important advantages such as excellent tissue penetration, high spatial resolution,
and harmless radiation. There are two main types of contrast agents for MRI: gadolinium (Gd)
or manganese chelates [62], as T1-weighted positive agents and superparamagnetic iron oxide
nanoparticles (SPION) [63], as T2-weighted negative agents, respectively. RI is based on the
relaxation of proton spin in the presence of a strong magnetic field. hen a magnetic field is present,
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proton spin can be aligned parallel or antiparallel to the magnetic field direction. By the application of
specific radiofrequencies (RF), it is possible to excite the proton spin to antiparallel orientation which
will recover its low-energy state (parallel) when RF is ceased by two different relaxation mechanisms:
longitudinal or T1 relaxation and transverse or T2 relaxation [63]. The use of these contrast agents
enhances the variations between healthy and diseased tissues. Gd complexed with bovine serum
albumin have been anchored on Dox-loaded MSN to act as redox-responsive poreblockers and MRI
contrast agent [64]. The selectivity of this system against breast cancer cells was enhanced by grafting
hyaluronic acid (HA) on MSN because of its high binding efficacy to the CD44 receptor located on
the membrane of these tumoral cells. Thus, once the nanocarrier are engulfed by the tumoral cell,
the higher glutathione concentration in the cytosol triggers the Dox release while the presence of Gd
allows the in vivo monitorization of the nanocarrier biodistribution by MRI. Ultrasmall manganese
oxide nanoparticles (USMO) (around 3 nm of diameter) were synthesized on the pore outlets of MSN
forming core-shell nanoparticles MSN@USMO able to retain Dox in the pore network [65]. Drug release
takes place by dissolution of the manganese nanoparticles which is accelerated in the mild acidic
conditions present in the tumoral environment. Interestingly, the release of Mn2+ which happened in
the USMO dissolution process enhanced the T1-weighted MR contrast capacity providing excellent
MRI images of the diseased zone (Figure 3).
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of manganese nanoparticles in mild acidic conditions. Reproduced with permission from [65], 
American Chemical Society, 2018. 
In other example, MSN loaded with tirapazamide, a bioreductive prodrug, which is only toxic 
in hypoxic cells, was alternatively coated with per-O-methyl-b-cyclodextrin-grafted-hyaluronic acid 
(HA-CD) and the porphyrin photosensitizer TPPS4 via layer-by-layer (LbL) assembly strategy [66]. 
Gd3+ was introduced in the system by chelation with TPPS4. This system was selectively engulfed by 
squamous cell carcinoma tumoral cells which overexpress CD44 receptor that binds to HA and 
release their payload in the presence of hyaluronidase, which is usually present in tumoral tissues. 
This nanocarrier is capable of destroying the tumoral cells by the synergic action of the released 
tirapazamide and singlet oxygen species produced by NIR laser radiation owing to the presence of 
photosensitizers. Additionally, the nanocarrier biodistribution can be monitored by fluorescence 
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transport Dox to breast cancer cells following their accumulation in murine models by MRI [70]. In 
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In other exa ple, S loaded ith tirapaza ide, a bioreductive prodrug, hich is only toxic
in hypoxic cells, as alternatively coated ith per- - ethyl-b-cyclodextrin-grafted-hyaluronic acid
( - ) and the porphyrin photosensitizer TPPS4 via layer-by-layer (LbL) asse bly strategy [66].
d3+ was introduced in the system by chelation with TPPS4. This system was selectively engulfed
by squamous cell carcinoma tumoral cells which overexpress CD44 receptor that binds to and
release their payload in the presence of hyaluronidase, hich is usually present in tu oral tissues.
This nanocarrier is capable of destroying the tu oral cells by the synergic action of the released
tirapaza ide and singlet oxygen species produced by NIR laser radiation owing to the presence
of photosensitizers. Additionally, the nanocarrier biodistribution can be onitored by fluorescence
i aging and RI.
SPI co bine their ability to act as T -relaxation contrast agent ith their capacity to increase
the surrounding temperature in the presence of an alternative magnetic field (AMF). This last property
has been widely employed to destroy solid tumors by magnetic hyperthermia because tumoral cells
are more sensitive to temperature than healthy ones [67]. SPION have been incorporated in MSN
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(MSN@SPION) to provide magnetic-responsive properties which have been used to trigger the release
of different therapeutic agents [68]. This approach presents the advantage of the synergism achieved
with the temperature increase in the tumoral tissue that enhances the effect of some chemotherapeutic
agents [69]. Cai et al. have developed MSN which contains SPION to transport Dox to breast cancer
cells following their accumulation in murine models by MRI [70]. In other work, Shi et al. have
anchored SPION on amine-functionalized hollow MSN surface exploiting the affinity of SPION surface
by amino groups [71]. The surface of these nanocarriers was coated with polydopamine which
improved their colloidal stability and served as NIR absorber that allowed the destruction of tumoral
cells by photothermal therapy. The accumulation of nanoparticles on the tumoral tissue was followed
by MRI and photoacoustic imaging. MSN@SPION have been employed in suicide gene therapy for
hepatocellular carcinoma [72]. This therapy is based on the introduction of genes into the tumoral
cell genome to express specific enzymes that activate pro-drugs provoking the cellular destruction.
In this work, the herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) is conjugated
with a copolymer of PEG and poly-lysine which provides positive charges on the plasmid conjugate
that allows the retention on the surface of negatively charged MSN surface, which was previously
functionalized with carboxylate groups. The adsorption of the plasmid on the nanocarrier surface
increases its protection against external insults and enhanced its blood circulation time. Moreover,
the presence of poly-lysine facilitated the endosomal escape of the nanocarrier once engulfed by tumoral
cells by proton-sponge effect. The application of an alternative magnetic field provoked the temperature
to increase up to 46 ◦C which enhanced the effect of suicide gene therapy because hyperthermia roused
the dormant cells in G0 phase making them more susceptible to gene transfection. Finally, the use of
external magnetic fields improved the retention of these nanocarriers in the tumoral tissue which was
monitored by MRI. MSN@SPION decorated with folic acid as targeting agent have been employed
to selectively deliver quercetin, a natural flavonoid with multiple antitumoral properties, to human
colorectal carcinoma cells [73]. Instead of SPION, other magnetic alloys in nanoparticulate state that
FePt is incorporated in MSN to provide magnetic hyperthermia and MRI contrast agent capacities [74].
One important advantage is that FePt nanoparticles exhibit NIR absorption that allowed to combine
the capacity to release chemotherapeutic drugs located within the pore network of MSN with PTT.
6. Radionuclide-Based Theranostics
The incorporation of radioactive elements in nanoparticles allows their detection employing
different techniques being positron emission tomography (PET) one of the most widely used. PET is
based on the emission of positrons by radioactive elements which are combined with electrons of
the surrounding tissue producing gamma-rays that are detected producing 3D imaging of the tissue.
18F is a popular positron emitter which is transported to the surface of MSN for tumor imaging by
PET following a two-step process based on biorthogonal click chemistry reactions [75]. In this elegant
strategy, MSN were functionalized with a strained cyclooctine, dibenzocyclooctyne (DBCO) and the
nanoparticles were injected in the tail of tumor-bearing mice. After 24 h, the nanoparticles were
accumulated in the tumoral tissue by EPR effect, azide-PEG-18F was injected being retained in the
tumoral tissue because of the specific reaction between the azide groups and DBCO allowing the
tumor imaging by PET. A similar recognition process has been reported employing 64Cu-tetrazine
molecular PET probe [76]. In this work, MSN were employed to deliver a polymer which contained
trans-cyclooctine to the tumoral tissue. The released macromolecules reacted with the PET probes
which were administered separately by the specific reaction between the tetrazine and cyclooctyne
group of each moiety retaining the 64Cu in the tumoral tissue. Large-pore MSN that contained
neoantigen peptides, specific immunostimulating oligonucleotide strands (CpG), 64Cu, and chlorin e6
have been employed to trigger immune responses against tumors by combination of PDT, because
of the presence of chlorin e6, and the release of immunostimulating agents [77]. These nanocarriers
were administered in bilateral two-tumor model with MC-38 colon carcinoma. Once confirmed their
accumulation in the tumoral lesions by PET, tumors located in the right flank of the animals were
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irradiated with NIR laser (660 nm, 50 mW/cm2 during 15 min) while the left-flank tumors were not
irradiated (Figure 4). The animals treated with these nanocarriers showed a significant tumor shrinkage
even in the non-irradiated tumors by abscopal effect that proves the efficient recruitment of immune
system in the antitumoral response. The radical oxidative species released by PDT provoked the
immunogenic cell death of the tumoral cells, which is a specific death mechanism that release danger
signals to the surroundings that stimulated immune responses [78]. PDT in combination with the
release of immunostimulating agents induced dendritic cell stimulation and CD8 + T cell eliciting
effective antitumoral immune response.
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7. Conclusions
The use of nanoparticles as drug carriers provides an excellent opportunity to deliver therapeutics
to diseased tissues with high selectivity and fine control in the drug release process. These properties
have paramount importance in the treatment of solid tumors because of the high toxicity of the
conventional antitumoral drugs. The passive accumulation of nanocarriers in tumoral tissues by EPR
in combination with the nanocarrier surface decoration with targeting moieties reduces the side toxicity
associated to antitumoral drugs. Theranostic nanocarriers provide one additional property which is
the possibility to monitor their localization into the host and to provide information about disease
progression and the effect of their own therapy. Therefore, multifunctional nanocarriers endowed
with imaging and controlled release properties have been described to treat malignancies yielding
information about their efficacy simultaneously. Among the different types of nanocarriers MSN
constitute an excellent platform because of their unique properties. The external surface of MSN
can be easily functionalized with multiple chemical groups allowing to anchor a vast number of
imaging agents, from small fluorophores to other nanoparticles able to act as contrast agents in multiple
imaging techniques. This property, in combination with the excellent cargo capacity of this material
convert MSN into a powerful theranostic nanomaterial (Table 1). Silica is considered as generally
recognized as safe (GRAS) material by US Food and Drug Administration (FDA) and several studies
have concluded that MSN are biocompatible and harmless [82]. However, knowledge is needed in
order to evaluate the safety of MSN depending of the administration route, particle size, surface
decoration, and degradability in physiological fluids [83,84]. Additionally, long-term toxicity studies
about the chronic administration of MSN are needed. Recently, Mohammadpour et al. have evaluated
the effect of the intravenous administration of silica nanoparticles with different sizes and porosities
for one year in animal models showing scarce toxicity [85]. The development of industrial synthetic
routes which yield large amounts of high quality MSN with reproducibility between batches is also a
challenge. There is much work to do but the future of these MSN theranostics is full of potential and
they would provide powerful tools in the oncology clinical field.
Pharmaceutics 2020, 12, 957 11 of 16
Table 1. Summary of the different theranostics MSN according with the imaging technique, payload, and stimuli which trigger the therapeutic response.
Type Stimuli Payload Therapeutic Application Ref
Optical NIR Indocyanine green (ICG) PDT [38]
MMP PLGVR peptide and CPT Chemotherapy [39]
NIR DIR PTT [40]
NIR Aptamer YQ26 and Cy5.5 Fluorescent imaging of tumoral blood vessels [41]
Gluthation/caspases Polydisulfides, small molecule inhibitors, anti-miR-21 Chemotherapy [42]
VIS CD and Dox Chemotherapy [43]
NIR CuS Hyperthermia [46]
Photoacustical NIR ICG and MTX Chemotherapy [47]
NIR ICG and NaYF4/Yb/Er nanoparticles Hyperthermia [48]
NIR Gd and Dox Hyperthermia/chemotherapy [49]
NIR PFP and gold nanorods Hyperthermia [50]
Ultrasound US p(MEO2MA)/THPMA and Dox Chemotherapy [57]
US Co-injection with cavitation nuclei Tumoral tissue penetration enhancers [61]
Magnetic resonance Glutathione Gd@BSA/Dox Chemotherapy [64]
pH USMO/Dox Chemotherapy [65]
Hyaluronidase/NIR HA-CD/Gd/tirapazamide Chemotherapy/PDT [66]
Magnetic field PNIPAM/NHMA/SPION/Dox Chemotherapy/hyperthermia [69]
NIR Polydopamine/SPION Hyperthermia [71]
Magnetic field Polylysine/HSV-TK/GCV/SPION Gene suicide/Hyperthermia [72]
Radionucleotide-based NIR neoantigen peptides/CpG/chlorin e6 Immunotherapy/PDT [77]
NIR 64Cu/SN38 Chemotherapy [79]
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Abbreviations List
CD carbon dots
CPT camptothecin
DBCO dibenzocyclooctyne
Dox doxorubicin
ECM extracellular matrix
EPR enhanced permeation and retention effect
FDA food and drug administration
HER2 human epidermal growth factor receptor 2
ICG indocyanine green
MRI magnetic resonance imaging
MSN mesoporous silica nanoparticles
MTX mitoxantrone
NIR near infrared radiation
PA photoacoustic imaging
PDT photodynamic therapy (PDT)
PEG polyethyleneglycol
PET positron emission tomography
PFP perfluoropentane
PTT photothermal therapy
RF radiofrequencies
SPION superparamagnetic iron oxide nanoparticles
THPMA 2-tetrahydropyranyl methacrylate
US ultrasounds
UV ultraviolet light
VIS visible light
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